Cipla receives FDA approval for generic version of Valeant antidepressant
pharmafile | August 30, 2016 | News story | Manufacturing and Production, Sales and Marketing | Cipla, FDA, Valeant, Wellbutrin
Indian multinational pharma and biotech company Cipla has announced that its US arm InvaGen Pharmaceuticals has received approval from the FDA to market its generic bupropion hydrochloride extended release tablets for the treatment of major depressive disorder.
The firm’s product is a generic version of Valeant’s Wellbutrin XL tablets, available in 150mg and 200 mg. Valeant’s drug generated sales of approximately $792 million for the 12 month period ending June 2016.
The product is available for shipping immediately. Cipla’s shares have risen 0.76% to Rs 571.50 apiece on the BSE at the time of this writing.
Matt Fellows
Related Content

Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …

MedPharm announces US FDA inspection of North Carolina manufacturing facility
MedPharm has announced that the US Food and Drug Administration (FDA) has completed a successful …

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …




